Synthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles by Wang, Jun et al.
© 2011 Wang et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2011:6 203–211
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
203
OrIgINAL reseArch
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/IJN.S16165
Synthesis and antitumor efficacy  
of daunorubicin-loaded magnetic nanoparticles
Jun Wang1
Baoan chen1
Jian chen1
Xiaohui cai1
guohua Xia2
ran Liu1
Pingsheng chen2
Yu Zhang3
Xuemei Wang3
1Department of hematology and 
Oncology, Zhongda hospital, school 
of Medicine, southeast University, 
Nanjing, china 210009; 2Medical 
school, southeast University, 
Nanjing; 3state Key Laboratory of 
Bioelectronics, southeast University, 
Nanjing, china 210009
correspondence: Baoan chen 
Department of hematology,  
The Affliated Zhongda Hospital,  
southeast University, Nanjing 210009,  
People’s republic of china 
Tel +86 25 8327 2006 
Fax +86 25 8327 2011 
email cba8888@hotmail.com
Background: A promising approach to optimize the disposition of daunorubicin-loaded 
magnetic nanoparticles (DNR-MNPs) was developed to minimize serious side effects of 
systematic chemotherapy for cancer.
Methods: The physical properties of DNR-MNPs were investigated and their effect on leukemia 
cells in vitro was evaluated by a standard WST-1 cell proliferation assay. Furthermore, cell apoptosis 
and intracellular accumulation of DNR were determined by FACSCalibur flow cytometry.
Results: Our results showed that the majority of MNPs were spherical and their sizes were 
from 10 to 20 nm. The average hydrodynamic diameter of DNR-MNPs in water was 94 nm. 
The in vitro release data showed that the DNR-MNPs have excellent sustained release property. 
Proliferation of K562 cells was inhibited in a dose-dependent manner by DNR in solution   
(DNR-Sol) or by DNR-MNPs. The IC50 for DNR-MNPs was slightly higher than that for 
DNR-Sol. DNR-MNPs also induced less apoptosis in K562 cells than did DNR-Sol. Detection 
of fluorescence intensity of intracellular DNR demonstrated that DNR-MNPs could be taken 
up by K562 cells and persistently released DNR in cells.
Conclusion: Our study suggests that optimized DNR-MNPs formulation possesses sustained 
drug-release and favorable antitumor properties, which may be used as a conventional dosage 
form for antitumor therapy.
Keywords: daunorubicin, magnetic iron oxide nanoparticles, drug delivery system, target 
selection, K562 cells
Introduction
Chemotherapy is the foundation of treatment for the vast majority of cancers, including 
hematologic malignancies. Daunorubicin (DNR), one of the anthracycline antitumor 
agents, has been widely used in the treatment of acute myelocytic leukemia and acute 
lymphocytic leukemia. Its anticancer effect results from interference with DNA, 
reactive oxygen species, DNA topoisomerase I and II, metal ions, and induction of 
apoptosis.1 Nevertheless, the clinical use of DNR has been impeded by its serious 
side effects, including cardiotoxicity, myelosuppression, and oral ulcers.2 Nowadays, 
it is considered important to achieve maximum antitumor effects while minimizing 
undesirable side effects associated with high dosages of chemotherapy.
Nanotechnology holds tremendous promise for the diagnosis and treatment of 
cancer.3,4 Recently, nanoparticle-based drug delivery systems have been used in an 
attempt to target specific delivery of drugs and reducing dose-limiting side effects, and 
these play an important role in raising target/nontarget concentration ratios, increasing 
drug residence at the target site, and improving cellular uptake and intracellular International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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stability.5 Scientists have studied drug delivery systems for 
many years, and recent achievements are very promising.6–8 
Drug delivery systems have been developed by incorporating 
drugs into biodegradable polymeric nanoparticles, liposomes, 
solid lipid nanoparticles, surfactant-modified or lipid-mod-
ified hydrogels, or complex nonviral gene transfection sys-
tems.9 Biocompatible and biodegradable superparamagnetic 
iron oxide nanoparticles (MNPs), which can be targeted to 
desired sites by using an external magnet field, lose their 
magnetic properties once the magnet is removed.10 They have 
been used widely in various biomedical applications, such 
as enhanced resolution magnetic resonance imaging, tissue 
repair, drug delivery, cellular/molecular tracking, cell separa-
tion, tissue targeting, and transfection.11 Additionally, MNPs 
can be loaded with drugs and escape from the macrophages 
when they are coated with a biocompatible polymer.12 In view 
of these features, they are excellent candidates for targeted 
drug delivery. However, the drug loaded on the surface of 
MNPs by mechanical absorption will be released rapidly 
after intravenous injection, causing very limited amounts of 
drug to arrive at target sites.
In order to minimize side effects and maximize the 
efficacy of DNR, we have developed an innovative DNR-
MNPs formulation for sustained release of DNR, in which 
the iron oxide core is firstly coated with oleic acid and DNR 
is stored there, then stabilized by Pluronic F-127®. The 
physical characteristics of DNR-MNPs, including mor-
phology, particle size, zeta potential, drug-loading capacity 
and encapsulation efficiency, kinetics of DNR release from 
magnetic nanoparticles in vitro, and magnetic properties, 
were comprehensively analyzed. Furthermore, the cytotoxic 
effects of the DNR-MNPs formulation on leukemia cells 
and induction of apoptosis were observed, and the efficacy 
of drug delivery was further investigated.
Materials and methods
Materials
Iron chloride hexahydrate (FeCl3 ⋅ 6H2O) and iron sulfate 
heptahydrate (FeSO4 ⋅ 7H2O) were obtained from Sinopharm 
Chemical Reagent Co., Ltd (Shanghai, China). Ammonium 
hydroxide (NH4 ⋅ OH) and oleic acid were acquired from 
Shanghai Lingfeng Chemical Reagent Co Ltd (Shanghai, 
China). Daunorubicin hydrochloride (DNR ⋅ HCl) was pur-
chased from Jinan Huifengda Chemical Co., Ltd (Shandong, 
China), and its stock solution was freshly prepared and 
stored in the dark at 4°C. Pluronic F-127 was obtained from 
Sigma-Aldrich (St. Louis, MO). The WST-1 cell proliferation 
and cytotoxicity assay kit was obtained from Beyotime 
Institute of Biotechnology (Jiangsu, China). The Annexin 
V-FITC apoptosis detection kit was obtained from Nanjing 
KeyGen Biotech Co., Ltd (Nanjing, China). All reagents 
were of analytical grade.
Preparation of magnetic nanoparticles
Iron oxide nanoparticles were prepared by coprecipitation of 
Fe (III) and Fe (II) with ammonium hydroxide in a nitrogen 
environment. In brief, ferric chloride hexahydrate 26 g and 
ferrous sulfate heptahydrate 18 g were dissolved in 50 mL of 
deionized water and heated to 70°C. Then 50 mL of ammonium 
hydroxide (25%) and 5 g of oleic acid were sequentially 
added. After 30 minutes, the temperature was increased to 
80°C and maintained for one hour. The products, ie, oleic 
acid-coated iron oxide nanoparticles, were cooled to room 
temperature and extracted by a magnet. After being washed 
with ethanol and finally with deionized water, the precipitates 
were lyophilized and stored at room temperature.
synthesis of daunorubicin-loaded 
magnetic nanoparticles
The formulation was developed as previously described.13 
Briefly, 450 mg of oleic acid-coated nanoparticles were 
dispersed in 45 mL of deionized water, and then 150 mg 
of Pluronic F-127 was added. The mixtures were stirred 
on a magnetic stir plate overnight at room temperature and 
centrifuged at 1000 rpm for 10 minutes at 10°C to obtain the 
oleic acid-coated and pluronic-stabilized iron oxide solution. 
The iron concentration in the aqueous dispersion of magnetic 
nanoparticles was detected by the 1, 10-phenanthroline colo-
rimetric method. The hydrophobic DNR solution was then 
prepared by adding triethylamine 12 µL to a DNR-methanolic 
solution (5 mg/mL),14 and 600 µL of the solution obtained was 
added dropwise into an aqueous dispersion of MNPs (30 mg 
of nanoparticles in 7 mL of water) by violent magnetic force 
stirring for 16 hours to make the drug enter into the oleic acid 
layer. The unloaded free drug was separated from the MNPs 
by a magnet. Briefly, a magnet outside of the vial was used 
to attract the drug-loaded MNPs for five hours, and then the 
liquid was removed carefully without disturbing the MNPs. 
The drug-loaded MNPs were resuspended in deionized water 
and washed twice to obtain the synthesized DNR-MNPs.
Morphology and appearance of MNPs
The particle size and morphology of MNPs were observed 
by transmission electron microscopy (TEM; JEM-2100; 
JEOL, Tokyo, Japan). Briefly, the lyophilized MNPs were 
dispersed in deionized water with a water-bath sonicator for International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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several minutes. A drop of MNPs solution was placed on a 
Formvar-coated copper TEM grid (150 mesh) and allowed 
to air dry for TEM observation.
Fourier transfer infrared spectra
The Fourier transfer infrared spectra of the specimens 
were recorded in the range of 400–4000 cm-1 using a 
Thermo Nicolet spectrometer (AVATAR 360 FT; Nicolet 
Instruments, Warwick, UK) at room temperature using the 
KBr pellet technique. The spectrum was recorded at room 
temperature, with a scanning speed of 20 cm-1 per minute 
and a spectral resolution of 4.0 cm-1.
crystallinity of MNPs by powder X-ray 
diffractometry
The crystallinity of the formed MNPs was measured with 
a powder X-ray diffractometer (XD-3A; Shimadzu, Kyoto, 
Japan). An accelerating voltage of 25 kV at 40 mA was used 
to produce vanadium-filtered Cr K α radiation between 20° 
and 90° at 27°C.
size and zeta potential of DNr-MNPs
The average hydrodynamic size of the DNR-MNPs was 
determined by dynamic laser scattering (Nano ZS90; Malvern 
Instruments, Westborough, MA). All measurements were done 
with an angle detection of 90° at 25°C after the dispersion 
was diluted to an appropriate volume with deionized water 
(refractive index = 1.330, diluent viscosity = 0.890 cP). 
The zeta potential of the DNR-MNPs was measured at 
22°C using a Zeta Plus zeta potential analyzer (Brookhaven 
Instruments, Holtsville, NY). The samples were diluted with 
deionized water and measured in automatic mode (voltage 
4.00 Vs, wavelength 658 nm).
Detection of DNr loading 
by high-performance liquid chromatography
Drug loading of the DNR-MNPs was detected by high-
performance liquid chromatography. Less than 2 mg of 
lyophilized DNR-MNPs were dispersed in 2 mL of methanolic 
solution in chloroform (12.5% v/v) by shaking at a speed of 
100 rpm for 24 hours and then centrifuged for 10 minutes 
at 16,000 rpm. For each sample, 100 µL of supernatant was 
diluted in 2 mL of methanolic-chloroform solution. Analysis 
of the sample was performed using a high-performance liquid 
chromatography system (Shimadzu, Kyoto, Japan) with a Sci-
ence C18 column (4.6–250 mm, 5 mm; Shimadzu) and a VP-
ODS C18 column (Shimadzu) at a detection wavelength of 
480 nm and an excitation wavelength of 560 nm, respectively. 
The concentration of DNR from 0.005 to 10 µg/mL was 
used to construct a calibration curve, and the DNR-loading 
capacity and encapsulation efficiency of nanoparticles were 
calculated as DL = We/Wp × 100%, EE = We/Wt × 100% 
(DL, drug loading capacity; EE, encapsulation efficiency; We, 
weight of DNR encapsulated in nanoparticles; Wp, weight of 
drug-loading magnetic nanoparticles; and Wt, total weight 
of DNR added).
Kinetics of DNr release from magnetic 
nanoparticles
To study the kinetics of DNR release from MNPs, lyophilized 
DNR-MNPs were dispersed in 2.5 mL of phosphate-
buffered saline (pH = 7.4, containing 0.1% w/v Tween-80, 
Tween–  phosphate-buffered saline), and then placed in a 
dialysis membrane bag with a molecular weight cutoff 
of 8,000–14,000 Da. The dialysis membrane bag was 
bathed in a tube containing the same volume of Tween– 
phosphate-buffered saline and the tube was placed in a 
shaker bath at 37°C. The   buffer was removed completely at 
different time intervals and complemented with fresh buffer. 
Tween-80 was added to keep sink conditions in the release 
experiments. The amount of DNR in buffer was analyzed 
by measuring the fluorescence intensity at λex = 458 nm and 
λem = 591 nm.
Magnetization studies
The magnetization of lyophilized DNR-MNPs was measured 
by a vibrating sample magnetometer integrated in a physical 
property measurement system (PPMS-9; Quantum Design, 
San Diego, CA) up to 50000 Oe at 300 K.
cell culture
Human chronic myelogenous leukemia cells (K562 cells) 
were donated by the Institute of Hematology at the Chinese 
Academy of Medical Sciences. Cells were maintained 
in RPMI 1640 medium containing 10% heat-inactivated 
newborn bovine serum, 100 U/mL penicillin, and 100 µg/mL 
streptomycin at 37°C in a humidified 5% CO2 atmosphere, 
and passaged once every 2–3 days.
In vitro cytotoxicity assays
Cell viability was determined using a standard WST-1 cell 
proliferation assay. In brief, K562 cells were seeded in 
96-well plates (20,000 cells per well), and administered 
with different concentrations of DNR in solution (DNR-
Sol) or DNR-MNPs after four hours. The doses of DNR 
incorporated in MNPs were equal to the corresponding International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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concentration of DNR-Sol. The cells were treated with 
RPMI 1640 medium and MNPs without drug as controls 
for DNR-Sol and DNR-MNPs, respectively. After being 
incubated for 48 hours, 20 µL of WST-1 were added to 
each well and cultured for another four hours. The absor-
bance at 450 nm was determined using a microplate reader 
(Thermo Scientific Multiskan MK3, Boston, MA) and the 
viability was calculated as ODtreated cells/ODcontrol cells × 100%. 
Finally, dose-effect curves were made and IC50 values were 
calculated.
Flow cytometric apoptosis assay
Based on the IC50 values of the WST-1 assay, 0.9 µg/mL 
DNR was adopted to test cell apoptosis by FACSCalibur flow 
cytometry (Becton Dickinson, Franklin Lakes, NJ). Briefly, 
4 × 105 K562 cells were exposed to DNR or DNR-MNPs for 
48 hours and, after being washed with phosphate-buffered 
saline twice, the cells were suspended with 500 µL of bind-
ing buffer and labeled with 5 µL of Annexin V-FITC for 
15 minutes at room temperature in the dark. Thereafter, cell 
apoptosis was determined by flow cytometry using CellQuest 
software at excitation and   emission wavelengths of 488 nm 
and 575 nm, respectively, over one hour.
Fluorescence intensity of intracellular 
DNr
After incubation for 48 hours as described earlier, K562 cells 
were collected, washed three times with phosphate-buffered 
saline, and suspended with 500 µL phosphate-buffered saline. 
Intracellular accumulation of DNR was detected by flow 
cytometry. The relative fluorescence intensity was calculated 
as FItreated cells /FIcontrol cells.
statistical analysis
All experiments were performed three times in duplicate. Data 
were expressed as mean ± standard deviation. Statistical analy-
ses were performed using a parametric test (Student’s t-test) by 
means of SPSS software (version 13.0; SPSS Inc, Chicago, IL). 
A value of P , 0.05 denoted statistical significance.
Results
Physical characteristics of magnetic 
nanoparticles
The majority of oleic acid–pluronic-stabilized magnetic 
nanoparticles under TEM were spherical or nearly spherical, 
with particle sizes from 10 to 20 nm. In local fields of TEM, 
clusters of nanoparticles resulting from dehydration were 
also observed (Figure 1).
We examined the properties of pluronic-block copolymers 
as surface coatings for MNPs. Fourier transfer infrared 
spectra of MNPs formulation confirmed the anchoring of 
Pluronic F-127 onto the oleic acid-coated iron oxide core 
(Figure 2). The peaks appeared in the oleic acid-coated MNPs 
at 2920, 2853, and 1458 cm-1 owing to -CH2- asymmetric 
or symmetric stretching and bending vibrations of the 
hydrophobic oleic acid chain. The hydrophilic carboxyl 
group on the pure oleic acid caused asymmetric vibration 
of the C = O at 1708 cm-1,15 but was absent in the spectra 
of oleic acid-coated MNPs, suggesting that oleic acid was 
chemisorbed as a carboxylate head group on the surface of the 
iron oxide nanoparticles (Figures 2A and 2C). Furthermore, 
the spectrum peaks of oleic acid–pluronic-stabilized MNPs 
at 1250–1000 cm-1 representing -CH2- rocking and C-O-C 
stretch vibrations in polyethylene oxide (PEO)-polypropylene 
oxide (PPO) chains of Pluronic F-127 further confirmed the 
adsorption of each block copolymer to the surface of MNPs 
(Figures 2B and 2C).
To evaluate the crystal components, the diffraction peak of 
MNPs was analyzed by X-ray diffraction. Figure 3 indicated 
that the majority of the iron oxide were magnetite (Fe3O4).
Figure 1 Oleic acid–pluronic-stabilized iron oxide nanoparticles under transmission 
electronic microscopy.
A
B
I
n
t
e
n
s
i
t
y
 
(
a
.
u
.
)
C
Wavenumbers (cm−1)
3000 2000 1000
Figure 2 Fourier transfer infrared spectra by a Thermo Nicolet spectrometer. 
A) Oleic acid-coated iron oxide, B) pure Pluronic F-127, and C) oleic acid–pluronic 
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The average hydrodynamic size of DNR-MNPs was 
94.71 nm with a polydispersity index of 0.132 (Figure 4). 
Apparently, the hydrodynamic diameter detected by the 
  particle size analyzer was due to the contribution of oleic acid 
and Pluronic F-127 associated with the nanoparticles and its 
hydration with water, which was larger than that of iron oxide 
observed under TEM. The zeta potential of DNR-MNPs in 
water was -21.31 ± 0.43 mV .
The drug-loading capacity and encapsulation efficiency 
were plotted in Table 1. The increase in the amount of drug 
was accompanied by an increase in drug-loading capacity. 
The encapsulation efficiency reached its peak when the added 
drug ratio was 10%, suggesting that 10% of added drug was 
the optimal dosage.
According to the in vitro release data (Figure 5), about 
20% of the cumulative drug release was in the first two 
days and 42% was in five days. After 25 days, the total drug 
release w 69%, indicating that the DNR-MNPs had excellent 
sustained-release properties.
The hysteresis loops of DNR-MNPs were measured by 
a vibrating sample magnetometer in the maximum applied 
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Figure 3 The crystallinity of pure Fe3O4 by X-ray diffractometry.
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Figure 4 hydrodynamic particle size distribution of daunorubicin-loaded magnetic 
nanoparticles in water measured by Zetasizer Nano Zs90 particle size analyzer.
Table 1 Daunorubicin loading in magnetic nanoparticles (mean ± 
standard deviation, n = 3)
Added  
(% w/w)
Loaded  
(% w/w)
Encapsulation   
efficiency (%)
5 2.07 ± 0.11 41.4
10 7.62 ± 0.47 76.2
20 11.49 ± 0.68 59.5
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Figure 5 release of daunorubicin from magnetic nanoparticles in vitro. 
Note: Data are mean ± standard deviation (n = 3).
field of 0 kOe at room temperature (Figure 6). The satura-
tion magnetization of the DNR-MNPs was 49.35 emu/g, 
and coercivity Hc was 7.6 Oe at room temperature. The 
samples showed typical superparamagnetic behavior at room 
temperature.
cytotoxicity of K562 cells
The dose-dependent curve was calculated when K562 cells 
had been exposed to DNR-Sol or DNR-MNPs for 48 hours 
(Figure 7). Loss of cell viability was notable with increasing 
doses of both DNR-Sol and DNR-MNPs. Compared with 
DNR-Sol, the IC50 value for DNR-MNPs was slightly higher 
(IC50/DNR-MNPs = 2.28 ± 0.63 µg/mL, IC50/DNR-Sol = 0.86 ± 
0.02 µg/mL, P , 0.05). The MNPs alone had no obvious 
cytotoxic effect on K562 cells, and even the cell viability was 
still above 80% when the concentration of MNPs reached 100 
µg/mL after treatment for 48 hours (Figure 8).
Apoptosis of K562 cells
The percentages of apoptosis in K562 cells treated with 
DNR-Sol and DNR-MNPs were 50.07% ± 7.39% and 
35.27% ± 5.27%, respectively (Figure 9), suggesting 
that DNR-MNPs had a slightly lower ability to induce 
  apoptosis of K562 cells when compared with DNR-Sol 
(P , 0.05).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Fluorescence intensity of intracellular 
DNr
Due to the autofluorescence feature of DNR, intracellular 
DNR in K562 cells could be detected by flow cytometry. 
After incubation for 48 hours, the relative fluorescence 
intensity of intracellular DNR in cells treated with DNR-
Sol and DNR-MNPs were 10.78 ± 2.53 and 10.79 ± 1.59, 
respectively. There was no statistically difference between 
them (P . 0.05, Figure 10).
Discussion
Chemotherapy has become one of the main strategies to treat 
most malignant tumors. However, there are some serious 
issues associated with systemic chemotherapy, including 
drug redistribution in the body and the high doses needed to 
reach target tissues in an effective concentration due to lack of 
site specificity. Because of toxicity to sensitive normal cells, 
nonspecific side effects emerge, including liver or kidney 
damage, bone marrow suppression, gastrointestinal reactions, 
and hair loss. Nanoparticle drug delivery systems have shown 
a potential to enhance the accumulation of anticancer agents 
in tumor cells.16 Optimization of these carriers continues 
today with the two objectives of reducing the amount of 
systemic distribution of the cytotoxic drug, thus reducing the 
associated side effects, and reducing the dosage required by 
more efficient localized targeting of the drug.17
Unlike normal tissues, cancer tissues usually consist of 
leaky blood vessels. Faced with fast-growing tumors, neo-
vascularization is frequently defective and coupled with poor 
lymphatic drainage, which allows enhanced permeation and 
retention of therapeutic nanodrugs (enhanced permeability 
and retention effect).18–21 Therefore, it is possible to exploit 
nanoparticles as drug vehicles in tumor therapy because of 
their active and passive accumulation in tumors after intrave-
nous injection. In addition, nanodrugs penetrate into target 
cancer cells via antibody- or ligand-mediated endocytosis, 
which increases the selective delivery of antineoplastic drugs 
to cancer cells or cancer-associated tissues, such as tumor 
vasculature, and limits their accumulation in healthy tissues. 
Thus, improvement of patient tolerance to chemotherapy, 
elevation of the clinical remission rate, and reversal of drug 
resistance in tumor cells can be realized.22–24
In this study, we have exploited iron oxide due to its bio-
degradability and biocompatibility as a nanocarrier system to 
transport DNR to the target site where it can exert its antitumor 
effects. In our DNR-MNPs formulation, iron oxide cores 
are coated with oleic acid and then modified by hydrophilic 
polymers to improve aqueous dispersion. Various polymers, 
such as polyvinylpyrrolidone, polylactic-co-glycolic acid, 
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and   polyethylene glycol, have been used as coating materials 
in aqueous suspension. Pluronics are amphiphilic synthetic 
polymers containing hydrophilic PEO blocks and hydrophobic 
PPO blocks arranged in a triblock structure, ie, PEO-
PPO-PEO.25 The hydrophobic PPO of pluronics anchor onto 
the oleic acid shell and hydrophilic PEO have strong affinity 
for water molecules, which are responsible for the aqueous 
dispersibility of the formulation. Meanwhile, the hydrophilic 
surface is able to reduce opsonization and   phagocytosis.26 
We can utilize the magnetic property of iron oxide cores in 
the DNR-MNPs formulation and apply an external magnetic 
field to magnetize drug delivery system to target tissue. The 
oleic acid shell, acting as a drug depot, allows water-insoluble 
drugs, like DNR, to participate in oleic acid and persistently 
release DNR for a long period of time. Pluronic F-127 has the 
ability to form micelles spontaneously. However, because the 
concentration used in our experiment is much lower than the 
critical micelle concentration (20 mg/mL),27 our formulation 
is different from that of micelles described previously.28,29 
Toxicity testing of MNPs without drug-loading confirms that 
they are nontoxic and safe. Compared with that described 
in Jain’s report,13 our formulation possesses slightly lower 
drug-loading capacity, which may be related to the significantly 
reduced particle size. Moghimi et al30 concluded that small size International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
210
Wang et al
and high hydrophilicity of nanoparticles lead to decreasing 
opsonization. Gupta et al31 reported that sizes between 10 
and 100 nm were the most effective for drug delivery because 
they could evade the reticulo-endothelial system (RES). 
Furthermore, our experimental model is in hematological 
malignancies, which is different to those used for solid tumors. 
According to the report of Moghimi et al,32 nanoparticles can 
penetrate into bone marrow easily when they are smaller than 
100 nm. Consequently, it seemed very important to control the 
particle size of our formulation. According to measurements 
using the particle size analyzer, an average DNR-MNPs size of 
94 nm meets our requirements. Previously we used albumin to 
incorporate MNPs and DNR, but we abandoned this because 
of the low drug-loading capacity (about 3%–5%), large particle 
size (.200 nm), difficulty in forming spheres, and poor disper-
sion in water (data not shown). Currently, our DNR-MNPs are 
easily dispersed in water, and the drug-loading capacity and 
encapsulation efficiency are 7.62% and 76.2%, respectively. 
In vitro drug release shows a biphasic pattern consisting of an 
initial burst release followed by sustained slow release over 
a prolonged period of time of up to several weeks. The drug 
loaded in the MNPs diffuses out from the oleic acid shell driven 
by a concentration gradient during the first few days, and then 
releases in a slow and sustained manner probably because of 
the dissociation of the OA layer from the iron oxide core. Dur-
ing the synthesis process, the physical characteristics of iron 
oxide do not change and it still possesses excellent superpara-
magnetic ability at room temperature. In in vitro cytotoxicity 
assays, the efficacy of DNR-MNPs is a little lower than that 
of DNR-Sol. However, at the termination of our experiment 
at 48 hours, only about 20% of the loaded DNR was released 
in vitro owing to the sustained-release action.
It is well known that apoptosis is a major mechanism of 
cell death. Similar results are found for the percentage of 
apoptotic K562 cells induced by DNR-Sol and DNR-MNPs. 
In a previous study by our group,33,34 daunorubicin-loaded 
magnetic nanoparticles of Fe3O4 were more effective than 
daunorubicin alone in multidrug-resistant cells. Our pres-
ent synthesis method is different to the previous one, which 
relied on mechanical absorption and polymerization, result-
ing in loose linkage of DNR and MNPs. With its excellent 
sustained-release properties, our DNR-MNPs formulation 
continued to release DNR after arriving at the target site 
without significantly elevating plasma DNR concentrations. 
The results of our flow cytometric assay demonstrate that there 
is no difference in the amount of DNR uptaken in K562 cells 
between the DNR-Sol group and DNR-MNPs groups. Only 
about 20% of DNR is released from the nanoparticles over two 
days, according to the results of our in vitro release studies, 
suggesting that DNR-MNPs are taken up by K562 cells and 
release DNR in cells in a sustained manner, other than cells 
ingest DNR released from nanoparticles extracellularly.
We conclude that our DNR-MNPs formulation is an 
effective drug delivery system for systemic administration. 
Furthermore, it decreases the side effects of high plasma DNR 
concentrations after intravenous injection effectively, prolongs 
the dosing interval, and improves patient compliance.
Conclusion
Our study demonstrates that the DNR-MNPs formulation 
has good aqueous dispersion, small particle size, high 
drug-loading capacity and encapsulation efficiency, and 
has the properties of sustained drug release and superpara-
magnetism. It is a promising systemic chemotherapy for 
leukemia and can be expanded for use on other cancers. 
Further research is needed to test the effects and pharma-
cokinetics of our DNR-MNPs formulation in vivo, and its 
precise mechanism of action.
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